Day One Biopharmaceuticals (DAWN) News Today $12.43 +0.20 (+1.64%) Closing price 04:00 PM EasternExtended Trading$12.46 +0.04 (+0.28%) As of 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period TimesSquare Capital Management LLC Sells 116,769 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)TimesSquare Capital Management LLC trimmed its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 6.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,710,926 shares of the company's stock after sFebruary 20 at 4:46 AM | marketbeat.comDay One Biopharmaceuticals (DAWN) Projected to Post Earnings on MondayDay One Biopharmaceuticals (NASDAQ:DAWN) will be releasing earnings after the market closes on Monday, February 24, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=664811)February 17, 2025 | marketbeat.comThe Goldman Sachs Group Has Lowered Expectations for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock PriceFebruary 12, 2025 | americanbankingnews.comDay One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025February 11, 2025 | globenewswire.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Recommendation of "Buy" by AnalystsFebruary 11, 2025 | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Buy" by AnalystsShares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have earned an average recommendation of "Buy" from the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buyFebruary 11, 2025 | marketbeat.comThe Goldman Sachs Group Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $43.00The Goldman Sachs Group cut their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a "buy" rating on the stock in a research report on Monday.February 10, 2025 | marketbeat.comDay One Biopharmaceuticals: A Successful Launch In Pediatric CancerFebruary 3, 2025 | seekingalpha.comTara Bancroft’s Buy Rating: Ojemda’s Promising Growth and Strong Financial ProspectsJanuary 31, 2025 | markets.businessinsider.comSG Americas Securities LLC Acquires Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 68,374 shares of the company's stock, valued at approximately $866,000. SJanuary 29, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Hennion & Walsh Asset Management Inc.Hennion & Walsh Asset Management Inc. increased its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 90.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 121,167 shares of the company's stock afterJanuary 19, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Buy" from AnalystsShares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have been given an average recommendation of "Buy" by the nine brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have issued a bJanuary 17, 2025 | marketbeat.comStrategic Positioning and Growth Potential of Day One Biopharmaceuticals: A Buy Rating Driven by Ojemda’s Market PenetrationJanuary 16, 2025 | markets.businessinsider.comBank of America Securities Reaffirms Their Buy Rating on Day One Biopharmaceuticals (DAWN)January 15, 2025 | markets.businessinsider.comOptimistic Outlook for Day One Biopharmaceuticals: Strong Sales Performance and Promising Pipeline Support Buy RatingJanuary 13, 2025 | markets.businessinsider.comDay One Biopharmaceuticals preliminary FY24 OJEMDA product revenue $57.2MJanuary 13, 2025 | markets.businessinsider.comDay One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate PrioritiesJanuary 13, 2025 | finance.yahoo.comDay One Biopharmaceuticals' (DAWN) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday.January 13, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Hits New 12-Month Low - What's Next?Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low - Here's WhyJanuary 10, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Price Target Cut to $25.00 by Analysts at Bank of AmericaBank of America cut their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday.January 7, 2025 | marketbeat.comTop 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)January 7, 2025 | seekingalpha.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Significant Decrease in Short InterestDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 18,100,000 shares, a decline of 7.1% from the November 30th total of 19,490,000 shares. Currently, 24.9% of the shares of the company are sold short. Based on an average trading volume of 1,090,000 shares, the days-to-cover ratio is presently 16.6 days.December 30, 2024 | marketbeat.comGeode Capital Management LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Geode Capital Management LLC grew its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 10.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,432,697 shares of the company's stock after buying an addDecember 29, 2024 | marketbeat.comDay One Biopharmaceuticals: Sales Figures In The CrosshairsDecember 25, 2024 | seekingalpha.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Buy" from BrokeragesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has earned an average rating of "Buy" from the nine research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommDecember 23, 2024 | marketbeat.comDay One to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | globenewswire.comFranklin Resources Inc. Has $55.34 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Franklin Resources Inc. lifted its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 2.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,869,632 shares of the company's stock after pDecember 17, 2024 | marketbeat.comDay One price target lowered to $34 from $39 at JonesResearchDecember 17, 2024 | markets.businessinsider.comWellington Management Group LLP Acquires 423,543 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Wellington Management Group LLP lifted its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 142.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 721,581 shares of the company's stock aDecember 16, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Charles Schwab Investment Management Inc. increased its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 14.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 507,448 shares ofDecember 12, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Takes Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Frazier Life Sciences Management L.P. purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 689,655 shares of the company'December 10, 2024 | marketbeat.comJanus Henderson Group PLC Grows Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Janus Henderson Group PLC lifted its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 18.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,177,197 shares of the company's stock after acquiring anDecember 7, 2024 | marketbeat.comDay One Biopharmaceuticals (DAWN) Gets a Buy from Piper SandlerDecember 6, 2024 | markets.businessinsider.comSamsara BioCapital LLC Lowers Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Samsara BioCapital LLC lowered its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 25.0% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 147,319 shares of the company's stock after selling 49,106 shares during the period.December 5, 2024 | marketbeat.comFmr LLC Has $103.25 Million Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Fmr LLC lifted its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 178.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,412,380 shares of the company's stock after acquiring an additional 4,75December 5, 2024 | marketbeat.comErste Asset Management GmbH Purchases New Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Erste Asset Management GmbH acquired a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 51,200 shares of the company's stock, valued at approximately $725,000. ErsteDecember 4, 2024 | marketbeat.comAlgert Global LLC Purchases 50,990 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Algert Global LLC boosted its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 248.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 71,487 shares of the company's stock after purchasing an addNovember 30, 2024 | marketbeat.comBraidwell LP Purchases 1,837,949 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Braidwell LP grew its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 60.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,873,853 shares of the company's stock after acquiringNovember 29, 2024 | marketbeat.comVestal Point Capital LP Buys 1,250,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Vestal Point Capital LP raised its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 100.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,500,000 shareNovember 29, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Buy" by BrokeragesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has received a consensus rating of "Buy" from the nine analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have issued a buy recNovember 28, 2024 | marketbeat.comWhy Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?November 27, 2024 | msn.comDay One Biopharmaceuticals announces R&D leadership changeNovember 22, 2024 | uk.investing.comDay One Biopharmaceuticals announces executive retirementNovember 22, 2024 | uk.investing.comDay One Biopharmaceuticals Announces Leadership TransitionNovember 21, 2024 | markets.businessinsider.comDay One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & DevelopmentNovember 20, 2024 | globenewswire.comFirst Turn Management LLC Makes New Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)First Turn Management LLC purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 947,878 shares of theNovember 19, 2024 | marketbeat.comShort Interest in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Rises By 12.8%Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 18,020,000 shares, a growth of 12.8% from the October 15th total of 15,980,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is currently 17.7 days. Currently, 26.4% of the shares of the company are short sold.November 18, 2024 | marketbeat.comDay One to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 18, 2024 | globenewswire.com59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLPGSA Capital Partners LLP bought a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 59,259 shares of the company's stock, valued at approximNovember 17, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 SharesNovember 13, 2024 | insidertrades.com Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Media Mentions By Week DAWN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼0.840.60▲Average Medical News Sentiment DAWN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼54▲DAWN Articles Average Week Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TG Therapeutics News Today Krystal Biotech News Today SpringWorks Therapeutics News Today Biohaven News Today Recursion Pharmaceuticals News Today PTC Therapeutics News Today Organon & Co. News Today Ultragenyx Pharmaceutical News Today Alvotech News Today Avidity Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DAWN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
